Lung Cancer News and Research

Latest Lung Cancer News and Research

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

Weekly growth hormone on course for phase III in children

A long-lasting formulation of human growth hormone appears to be as effective as standard daily treatment in paediatric patients with growth hormone deficiency, researchers reported at the European Society of Paediatric Endocrinology annual meeting in Dublin, Ireland.

2 Oct 2014

Initial congenital hypothyroidism severity predicts later cortical abnormalities

Research suggests that the persistent cognitive defects seen in children with congenital hypothyroidism, despite optimal care, are associated with altered cortical thickness.

2 Oct 2014

Nutritional supplement boosts growth in short, lean children

A balanced nutritional supplement promotes height and weight gain in lean prepubertal children with idiopathic short stature, show the findings of a randomised trial.

2 Oct 2014

Recommendations for nutritional rickets announced

New consensus recommendations for the management of nutritional rickets include universal vitamin D supplementation during the first year of life.

2 Oct 2014

Empirical sulphonylurea therapy an option for neonatal diabetes

A report of empirical sulphonylurea therapy in neonatal diabetes prior to genetic diagnosis highlights contrasting approaches to the problem.

2 Oct 2014

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

CNIO researchers discover new specific marker for cancer stem cells

Tumours are mosaics of cells that are morphologically and molecularly very different. In this cellular heterogeneity, it is calculated that only 1-2% of the tumour mass is made up of cancer stem cells, which over the past years have been suggested to be responsible for the origin of cancer and for the resistance to conventional chemical therapies.

30 Sep 2014

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.

30 Sep 2014

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

30 Sep 2014

Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.

30 Sep 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Cancer community joins coalition seeking Medicare coverage for CT lung cancer screening

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

Lung Cancer News and Research

Latest Lung Cancer News and Research

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Weekly growth hormone on course for phase III in children

Initial congenital hypothyroidism severity predicts later cortical abnormalities

Nutritional supplement boosts growth in short, lean children

Recommendations for nutritional rickets announced

Empirical sulphonylurea therapy an option for neonatal diabetes

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

CNIO researchers discover new specific marker for cancer stem cells

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Cancer community joins coalition seeking Medicare coverage for CT lung cancer screening

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in